AUROPHARMA

started as a single SSP plant in 1988.

Today, it’s a global generics force across 125+ markets. What powered this rise? Sharp execution, regulatory discipline, and a massive R&D engine with 1,500+ scientists pushing 700+ ANDAs. From APIs to high-value biosimilars, Aurobindo Pharma

has steadily widened its moat — proving that quiet consistency can beat noisy volatility. With new subsidiaries in the U.S. and fresh regulatory wins in 2025, the company is doubling down on global scale. Aurobindo Pharma— India’s silent compounding engine.